KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Total Debt (2016 - 2025)

Gilead Sciences (GILD) has disclosed Total Debt for 17 consecutive years, with $24.9 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Debt fell 6.65% year-over-year to $24.9 billion, compared with a TTM value of $24.9 billion through Dec 2025, down 6.65%, and an annual FY2025 reading of $24.9 billion, down 6.65% over the prior year.
  • Total Debt was $24.9 billion for Q4 2025 at Gilead Sciences, roughly flat from $24.9 billion in the prior quarter.
  • Across five years, Total Debt topped out at $30.2 billion in Q2 2021 and bottomed at $23.2 billion in Q3 2024.
  • Average Total Debt over 5 years is $25.8 billion, with a median of $25.2 billion recorded in 2022.
  • Peak annual rise in Total Debt hit 25.2% in 2021, while the deepest fall reached 14.99% in 2021.
  • Year by year, Total Debt stood at $26.7 billion in 2021, then fell by 5.49% to $25.2 billion in 2022, then dropped by 0.96% to $25.0 billion in 2023, then increased by 6.9% to $26.7 billion in 2024, then fell by 6.65% to $24.9 billion in 2025.
  • Business Quant data shows Total Debt for GILD at $24.9 billion in Q4 2025, $24.9 billion in Q3 2025, and $24.9 billion in Q2 2025.